Teva Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS INC
TEVA PHARMS INC has sixteen approved drugs.
There is one US patent protecting TEVA PHARMS INC drugs. There are three tentative approvals on TEVA PHARMS INC drugs.
Summary for Teva Pharms Inc
| US Patents: | 1 |
| Tradenames: | 16 |
| Ingredients: | 16 |
| NDAs: | 16 |
Drugs and US Patents for Teva Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 219686-003 | Jan 22, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | LO JUNEL FE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 219324-001 | Jun 22, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-001 | Nov 29, 2023 | RX | Yes | No | 11,072,586 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Teva Pharms Inc | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 217517-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 215737-001 | Aug 12, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Teva Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2019071111 | ⤷ Start Trial |
| European Patent Office | 3692021 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1343782 | 2010C/030 | Belgium | ⤷ Start Trial | PRODUCT NAME: PAZOPANIB, OPTIONNELLEMENT SOUS LA FORME DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE OU DE SON SOLVATE; AUTHORISATION NUMBER AND DATE: EU/1/110/628/01 20100616 |
| 0503785 | CA 2011 00026 | Denmark | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
| 2101777 | 201640021 | Slovenia | ⤷ Start Trial | PRODUCT NAME: AMBRISENTAN IN COMBINATION WITH TADALAFIL; NATIONAL AUTHORISATION NUMBER: EU/1/08/451/001-004; DATE OF NATIONAL AUTHORISATION: 20151120; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 1380301 | CA 2009 00017 | Denmark | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 |
| 1453521 | 300814 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
